DSM Biologics aims for global leadership position among independent contract manufacturers for the pharmaceutical industry

22-May-2001

DSM Biologics, a business unit of the DSM fine chemicals business group, today brought on stream a new 2,000-litre fermentation unit at its Montreal (Quebec, Canada) site for the preparation of biopharmaceuticals on the basis of cell cultures. This new CAN 9 million unit, which was officially opened by Peter Elverding, chairman of the DSM Managing Board, is DSM Biologics' response to the increased demand for fermentation capacity, in particular for the preparation of biopharmaceutical products.

ML51 Downstream Processing

ML31 Fermentor

The new fermentation unit consists of clean rooms and a fermentor train. The fermentor train consists of two seed fermentors of 50 and 320 litres for culturing cells and a 2,000-litre production fermentor. DSM Biologics amply meets the quality standards set by the pharmaceutical industry (cGMP). The DSM Biologics site in Montreal is jointly owned by DSM and Societé générale de financement du Québec (SGF).

Ambitions

The fact that the new unit was officially opened by DSM Managing Board chairman Peter Elverding underlined the importance of the role played by DSM Biologics' ambitions in DSM's transformation into a specialty company. The ceremony was also attended by representatives of the Province of Quebec, which supports the establishment and development of advanced biotechnological industries in the Montreal region.

Other news from the department

Most read news

More news from our other portals

Discover the latest developments in battery technology!